论文部分内容阅读
1996年10月在丹麦哥本哈报举行的第九届国际胃十二指肠病理学与幽门螺杆菌专题讨论会上报道的一项Ⅱ期研究结果表明,欧洲和美国协作生产了一种安全的、有免疫原性的幽门螺杆菌菌苗.在瑞士沃杜瓦大学和美国疫苗开发中心进行的一项研究中,24例幽门螺杆菌感染引起的慢性胃炎患者分为5组.各组分别接受安慰剂、20、60、180mg重组尿素酶加粘膜佐剂大肠杆菌不耐热毒素或佐剂.IgA抗体分泌细胞测定表明,尿素酶治疗组14例患者中的5例产生免疫应答.10例接受安慰剂或仅接受佐剂的患者均未产生免疫应答.10例接受安慰剂或仅接受佐剂的患者均未产生免疫应答.治疗组5例患者细菌水平减低,而对照组患者均未出现减低现象.最明显的副作用是佐剂引起的稀便.
A Phase II study reported in the Ninth International Gastro-duodenal Pathology and Helicobacter Pylori Symposium held in Copenhagen, Denmark in October 1996 showed that Europe and the United States collaborated to produce a safe Of immunogenic H. pylori vaccine in a study conducted by the University of Waduwa and the US Vaccine Development Center in Switzerland, 24 patients with chronic gastritis caused by Helicobacter pylori infection were divided into five groups, respectively Placebo, 20,60,180 mg of recombinant urease plus mucosal adjuvant Escherichia coli heat-labile toxin or adjuvant.IgA antibody-secreting cells assay showed that 5 of 14 patients in the urease-treated group had an immune response.10 cases None of the patients receiving placebo or adjuvant had an immune response.10 None of the 10 patients who received placebo or adjuvant had an immune response.Among the five patients in the treatment group, the bacterial levels decreased while none of the patients in the control group Reduce the phenomenon of the most obvious side effects are loose stools caused by adjuvant.